前列腺癌干细胞与去势抵抗性前列腺癌放射性耐受的研究进展

doi:10.3760/cma.j.issn.1004-4221.2017.11.023

摘要
图/表
参考文献()
相关文章 (1)
点击分布统计
下载分布统计

全文: PDF (774 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

前列腺癌经过去势治疗后有进展为去势抵抗性前列腺癌的可能。去势抵抗性前列腺癌对临床医生最大的挑战为其治疗抵抗特性。针对放疗耐受,相关研究认为与前列腺癌干细胞及前列腺癌干细胞相关miRNA相关。下文从去势抵抗性前列腺癌进展机制、前列腺癌干细胞及前列腺癌干细胞相关miRNA等方面介绍去势抵抗性前列腺癌放射性耐受的研究进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	朱逸飞
	曾浩

关键词 ：去势抵抗性前列腺癌, 前列腺癌干细胞, 放射性耐受, 微小核糖核酸

Abstract：

Prostate cancer tends to progress to castration-resistant prostate cancer within 24 months after castration. For the management of castration-resistant prostate cancer, the biggest challenge is therapeutic resistance which includes radiotherapy resistance. Relevant studies suggest that the radiotherapy resistance of castration-resistant prostate cancer is associated with prostate cancer stem cells and miRNA related to prostate cancer stem cells. This article reviews the research advances in the radiotherapy resistance of castration-resistant prostate cancer in terms of the possible mechanisms of castration-resistant prostate cancer, prostate cancer stem cells, and miRNA related to prostate cancer stem cells.

Key words： Castration Resistant Prostate Cancer Cancer stem cell Prostate cancer stem cell Micro-ribonucleic acid

收稿日期: 2016-11-07

基金资助:

四川省科技厅项目(2015SZ0230)

通讯作者: 曾浩,Email:kucaizeng@163.com

引用本文:

朱逸飞,曾浩. 前列腺癌干细胞与去势抵抗性前列腺癌放射性耐受的研究进展[J]. 中华放射肿瘤学杂志, 2017, 26(11): 1347-1349.

Zhu Yifei,Zeng Hao. Research advances in prostate cancer stem cells and radiotherapy resistance of castration-resistant prostate cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(11): 1347-1349.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2017.11.023 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2017/V26/I11/1347

[1] Perner S,Cronauer MV,Schrader AJ,et al. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer[J].Oncotarget,2015,6(34):35542-35555.DOI:10.18632/oncotarget.4689.
[2] 吴刚,吴登龙.前列腺癌干细胞的研究进展[J].中华男科学杂志,2015,21(2):170-174.DOI:10.13263/j.cnki.nja.2015.02.015.
Wu G,Wu DL.Prostate cancer stem cells:advances in current research[J].Chin J Androl,2015,21(2):170-174.DOI:10.13263/j.cnki.nja.2015.02.015.
[3] Li P,Yang R,Gao WQ.Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer[J].Mol Cancer,2014,13:55.DOI:10.1186/1476-4598-13-55.
[4] Wang L,Huang X,Zheng X,et al. Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy[J].Int J Biol Sci,2013,9(5):472-479.DOI:10.7150/ijbs.5855.
[5] Chen X,Rycaj K,Liu X,et al. New insights into prostate cancer stem cells[J][J].Cell Cycle,2013,12(4):579-586.DOI:10.7150/ijbs.5855.
[6] Savage N.Metastasis:resistance fighters[J].Nature,2015,528(7582):S128-129.DOI:10.1038/528S128a.
[7] Penning TM.Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)[J].J Steroid Biochem Mol Biol,2015,153:105-113.DOI:10.1016/j.jsbmb.2015.05.010.
[8] Beuzeboc P,Massard C.How to manage patients with CRPC?[J].Bull Cancer,2015,102(6):509-515.DOI:10.1016/j.bulcan.2015.04.015.
[9] Moselhy J,Srinivasan S,Ankem MK,et al. Natural products that target cancer stem cells[J].Anticancer Res,2015,35(11):5773-5788.
[10] Sampieri K,Fodde R.Cancer stem cells and metastasis[J].Semin Cancer Biol,2012,22(3):187-193.DOI:10.1016/j.semcancer.2012.03.002.
[11] Abel EV,Simeone DM.Biology and clinical applications of pancreatic cancer stem cells[J].Gastroenterology,2013,144(6):1241-1248.DOI:10.1053/j.gastro.2013.01.072.
[12] Calabrese C,Poppleton H,Kocak M,et al. A perivascular niche for brain tumor stem cells[J].Cancer Cell,2007,11(1):69-82.DOI:10.1016/j.ccr.2006.11.020.
[13] Reya T,Morrison SJ,Clarke MF,et al. Stem cells,cancer,and cancer stem cells[J].Nature,2001,414(6859):105-111.DOI:10.1038/35102167.
[14] Santer FR,Erb HH,McNeill RV.Therapy escape mechanisms in the malignant prostate[J].Semin Cancer Biol,2015,35:133-144.DOI:10.1016/j.semcancer.2015.08.005.
[15] Lang SH,Anderson E,Fordham R,et al. Modeling the prostate stem cell niche:An evaluation of stem cell survival and expansion in vitro[J].Stem Cells Dev,2010,19(4):537–546.DOI:10.1089/scd.2009.0291.
[16] Wyatt AW,Gleave ME.Targeting the adaptive molecular landscape of castration-resistant prostate cancer[J].EMBO Mol Med,2015,7(7):878-894.DOI:10.15252/emmm.201303701.
[17] Bartek J,Mistrik M,Bartkova J.Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer[J].Cancer Discov,2013,3(11):1222-1224.DOI:10.1158/2159-8290.CD-13-0679.
[18] Ni J,Cozzi P,Hao J,et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway[J].Int J Biochem Cell Biol,2013,45(12):2736-2748.DOI:10.1016/j.biocel.2013.09.008.
[19] Karantanos T,Evans CP,Tombal B.Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level[J].Eur Urol,2015,67(3):470-479.DOI:10.1016/j.eururo.2014.09.049.
[20] Buttigliero C,Tucci M,Bertaglia V,et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer[J].Cancer Treat Rev,2015,41(10):884-892.DOI:10.1016/j.ctrv.2015.08.002.
[21] Tucci M,Scagliotti GV,Vignani F.Metastatic castration-resistant prostate cancer:time for innovation[J].Future Oncol,2015,11(1):91-106.DOI:10.2217/fon.14.145.
[22] Grist E,de Bono JS,Attard G.Targeting extra-gonadal androgens in castration-resistant prostate cancer[J].J Steroid Biochem Mol Biol,2015,145:157-163.DOI:10.1016/j.jsbmb.2014.09.006.
[23] Goto Y,Kojima S,Nishikawa R,et al. MicroRNA expression signature of castration-resistant prostate cancer:the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker[J].Br J Cancer,2015,113(7):1055-1065.DOI:10.1038/bjc.2015.300.
[24] Frame FM,Pellacani D,Collins AT,et al. HDAC inhibitor confers radiosensitivity to prostate stem-like cells[J].Br J Cancer,2013,109(12):3023–3033.DOI:10.1038/bjc.2013.691.
[25] Jalava SE,Urbanucci A,Latonen L,et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer[J].Oncogene,2012,31(41):4460–4471.DOI:10.1038/onc.2011.624.
[26] Zhang W,Meng Y,Liu N,et al. Insights into chemoresistance of prostate cancer[J].Int J Biol Sci,2015,11(10):1160-1170.DOI:10.7150/ijbs.11439.
[27] Deng Q,Tang DG.Androgen receptor and prostate cancer stem cells:biological mechanisms and clinical implications[J].Endocr Relat Cancer,2015,22(6):T209-20.DOI:10.1530/ERC-15-0217.
[28] Ayub SG,Kaul D,Ayub T.Microdissecting the role of microRNAs in the pathogenesis of prostate cancer[J].Cancer Genet,2015,208(6):289-302.DOI:10.1016/j.cancergen.2015.02.010.
[29] Rane JK,Scaravilli M,Ylipaa A,et al. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets[J].Eur Urol,2015,67(1):7-10.DOI:10.1016/j.eururo.2014.09.005.
[30] Taylor B,Schultz N,Hieronymus H,et al. Integrative genomic profiling of human prostate cancer[J].Cancer Cell,2010,18(1):11–33.DOI:10.1016/j.ccr.2010.05.026.
[31] Nguyen HC,Xie W,Yang M,et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk,localized prostate cancer[J].Prostate,2013,73(4):346–354.DOI:10.1002/pros.22572.
[32] Tormo E,Pineda B,Serna E,et al. MicroRNA profile in response to doxorubicin treatment in breast cancer[J].J Cell Biochem,2015,116(9):2061-2073.DOI:10.1002/jcb.25162.
[33] Chang H,Kim N,Park JH,et al. Different microRNA expression levels in gastric cancer depending on Helicobacter pylori infection[J].Gut Liver,2015,9(2):188-196.DOI:10.5009/gnl13371.
[34] Attard G,Parker C,Eeles RA,et al. Prostate cancer. Lancet,2016,387(10013):70-82.DOI:10.1016/S0140-6736(14)61947-4.
[35] Yun EJ,Zhou J,Lin CJ,et al. Targeting cancer stem cells in castration-resistant prostate cancer[J].Clin Cancer Res,2016,22(3):670-679.DOI:10.1158/1078-0432.CCR-15-0190.